A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. · 2010
Read A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. by Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2916884.txt.
Introduction
Walker and co-authors mapped in 2010 which antibody targets explain the rare HIV patients whose blood neutralizes many virus strains at once. A vaccine will likely need such broadly neutralizing antibodies, yet nobody knew which viral sites the natural versions aim at. They dissected the serum of nineteen donors with the most potent cross-strain activity recorded, using a battery of binding and depletion tests.
In most donors, just one or two antibody specificities accounted for nearly all the breadth and power. Two targets dominated. One site spans the conserved parts of the viral spike's loops, defined by two famous antibodies. The other overlaps where the virus grips the CD4 entry receptor. A short shopping list for vaccine designers replaces a fog of possibilities.
Catalog record
| CREATOR | Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 80 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals By Laura M Walker, Melissa D Simek, Frances Priddy, Johannes S Gach, Denise Wagner, Michael B Zwick, Sanjay K Phogat, Pascal Poignard, Dennis R Burton, Alexandra Trkola Published in: PLoS Pathogens DOI: 10.1371/journal.ppat.1001028 ABSTRACT Abstract A protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing antibody (bNAb) response. Although the development of an immunogen that elicits such antibodies remains elusive, a proportion of HIV-1 infected individuals evolve broadly neutralizing serum responses over time, demonstrating that the human immune system can recognize and generate NAbs to conserved epitopes on the virus. Understanding the specificities that mediate broad neutralization will provide insight into which epitopes should be targeted for immunogen design and aid in the isolation of broadly neutralizing monoclonal antibodies from these donors. Here, we have used a number of new and established technologies to map the bNAb specificities in the sera of 19 donors who exhibit among the most potent cross-clade serum neutralizing activities observed to date. The results suggest that broad and potent serum neutralization arises in most donors through a limited number of specificities (1–2 per donor). The major targets recognized are an epitope defined by the bNAbs PG9 and PG16 that is associated with conserved regions of the V1, V2 and V3 loops, an epitope overlapping the CD4 binding site and possibly the coreceptor binding site, an epitope sensitive to a loss of the glycan at N332 and distinct from that recognized by the bNAb 2G12 and an epitope sensitive to an I165A substitution. In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera. INTRODUCTION The hallmark of most successful anti-viral vaccines is the ability to induce neutralizing antibodies [1], [2], [3], [4]. For HIV-1, NAbs have been shown to provide protection against viral challenge in non-human primate models [5], [6], [7], [8], [9], [10], [11], [12], [13], suggesting that a vaccine capable of inducing similar types of antibodies would provide benefit upon exposure to the virus. However, due to the extraordinary genetic diversity of the HIV-1, a successful vaccine will require the induction of antibodies that neutralize a wide spectrum of global circulating viral isolates, i.e. broadly neutralizing antibodies (bNAbs) [14]. Unfortunately, the development of an immunogen capable of eliciting bNAbs has not been met with success to date. Importantly, although NAbs generated during natural HIV-1 infection usually target immunodominant variable regions of the virus, recent studies have shown that 10–30% of infected individuals develop moderate to broadly neutralizing sera [15], [16], [17], [18]. These individuals are of considerable interest from a vaccine standpoint; understanding the antibody specificities that mediate potent cross-clade serum neutralizing activity may illuminate potential targets for HIV-1 immunogen design. In addition, knowledge of the epitopes targeted by the bNAbs can assist in the design of reagents, “baits”, to facilitate the isolation of broadly neutralizing monoclonal antibodies (bnMAbs) from these donors. BnMAbs can be used in molecular studies to help direct vaccine design [19], [20], [21]. Several studies have previously been performed to systematically analyze the NAb specificities in HIV-1 positive sera displaying varying degrees of neutralization breadth and potency [15], [16], [17], [18], [22], [23], [24]. In all of these studies, a series of complementary methods, such as selective removal of certain antibody specificities using antigen-coated beads, inhibition of neutralizing activity using linear peptides, and the use of chimeric viruses displaying specific epitopes, were used to define the epitopes targeted by NAbs in broadly neutralizing sera. Although the breadth of serum neutralization could rarely be mapped exclusively to a single epitope, several sera appeared to contain CD4bs and co-receptor binding site (CRbs)-specific antibodies that contributed to the overall breadth of serum neutralizing activity [16], [17], [22], [25]. In a minority of cases, sera were found to contain NAbs to the membrane-proximal external region (MPER) [16], [17], [23]. Arguably, one of the most significant results from these studies was that a substantial fraction of the serum NAbs appeared to target unidentified viral epitopes. Considering that most of the reagents used for characterization were based on monomeric gp120 and linear peptides, one possibility here is that the serum neutralization breadth is mediated by NAbs that recognize quaternary epitopes preferentially expressed on trimeric Env. Two recently described broad and potent NAbs, PG9 and PG16, fall into this category [26]. An important question that has arisen from serum studies concerns the number of NAb specificities that mediate broad serum neutralization. A few scenarios are possible; broad serum neutralization could be mediated by a very large number of neutralizing antibodies with limited breadth [27], a few relatively broad and potent neutralizing antibody specificities, or a single, extraordinarily broad and potent, neutralizing antibody specificity. Although these scenarios are not mutually exclusive, the latter two are more attractive in terms of vaccine design, as it appears far more practical to focus the immune response on a small number of conserved epitopes with a vaccine rather than on a large number of more variable epitopes. In a previous study, we screened sera from approximately 1,800 HIV-1 infected donors from Thailand, Australia, the United Kingdom, the United States, and several sub-Saharan African countries for neutralizing activity and identified donors who exhibit among the most broad and potent neutralizing serum activity observed to date [15]. The top 1% of samples screened, designated “elite neutralizers”, displayed particularly potent serum neutralizing activity against a cross-clade pseudovirus panel. These donors are valuable for understanding the development of broad responses and for the isolation of broad and potent neutralizing monoclonal antibodies. Notably, PG9 and PG16 were isolated from an individual who ranked in the top 5% of donors screened [26]. In this study, we have used a number of established and new techniques to map the broadly neutralizing antibody specificities in the serum of individuals who were ranked in the top 5% of neutralizers identified in our previous study, including elite neutralizers. Importantly, since many of our approaches rely on the use of functional assays, we defined the epitopes recognized by the broadly neutralizing serum antibodies in the context of the native trimer. Our results demonstrate that the broad neutralization in the sera of most of the individual donors can be associated with single or a small number of specificities. Across the donor panel, broad neutralization appears associated with 4–5 principal specificities. RESULTS Serum neutralizing activity and demographics of selected donors A total of 19 volunteers from diverse HIV-1 epidemics were characterized. Of the 19 volunteers, 63% were female, 26% male and 11% unknown. The median age of all volunteers was 38 with a median CD4 count of 414 and median log viral load of 4.07. All volunteers were infected for at least 3 years. Of the 19 donors analyzed, 14 ranked in the top 1% of neutralizers identified in our previous report (elite neutralizers), and the remaining 5 ranked in the top 5% of neutralizers. Figure S1 shows the serum neutralization profiles of the selected donors. Serum neutralization was assessed using an indicator cross-clade pseudovirus panel that has previously been shown to be predictive of neutralization breadth and potency over